What is different about PAT these days? I asked. Unlike a few years ago, he said, every firm has committed substantial resources and has a defined organizational strategy to approach PAT. The manufacturing segment of pharma has finally accepted PAT for real, he said.Some firms have been vocal about their PAT efforts, others not so. While he wont name names, Klevisha says some of the firms leading the pack in terms of progressive PAT strategies are those we hear least from.Whats the greatest risk firms face in implementing PAT? There are two, Klevisha said. First, they have to make sure that they have a sufficient staffing commitment to support the deployment of a PAT system. This includes having people qualified to transfer that knowledge to the manufacturing staff. Theres a very long learning curve for PAT applications, he added, and firms need to commit to thorough training programs for personnel.Finding experts to train the manufacturing ranks is not easy, he said. Process analysis experts from chemistry, defense, and telecom are in heavy demand, Klevisha said. The challenge is that these individuals dont have experience in a pharmaceutical environment.The second greatest risk is validation of PAT-enabled processes. The industry has a good sense of validation and equipment qualification, he said. But that has to be rethought for PAT. Traditional validation processes are too time-consuming and expensive. Costs of PAT equipment, in fact, can be dwarfed by the cost of validating its use, Klevisha said. Understanding the science behind PAT will be key for firms to solve validation issues.An understanding of processes grounded in science is, of course, what FDA is looking for. I asked Klevisha what FDAs PAT initiative has meant to his and Brukers business. Bruker has focused on PAT instrumentation for more than 12 years, he noted. But for most of those years, few pharmaceutical firms expressed even the slightest interest in process analytical technologies and systems. As a result, Bruker had no need to pursue technologies that it had within its grasp.That has changed dramatically since the initiative. Klevisha used the example of the companys Tandem on-line NIR device for monitoring tablet uniformity. After FDAs change of course, a major pharmaceutical firm asked Bruker to develop the device. Without PAT, we would not have developed it, he said. There would have been no market.Where is PAT headed in the next two or three years? "In that time, well have a firmer understanding of successful applications," Klevisha said. Right now, comprehensive PAT strategies are just getting under way and offer no real lessons to speak of. With trial and error will come experience. For Bruker, Klevisha believes, that will translate into better and less expensive tools and solutions, and easier and faster deployment.When payback is realized, investment will increase, he continued. Firms will demand robust, single-purpose, application-specific devices, he predicts. One company in another industry has already implemented more than a hundred different Bruker devices, Klevisha noted. Eventually, pharmaceutical firms will have similar needs.
|Bruker developed its Tandem on-line NIR device for monitoring tablet uniformity at a major pharma firm's request; there was no market for such an instrument before FDA began promoting PAT.|